ArticleTransboundary and emerging diseases2026
A Novel In-Cell ELISA With Superior Sensitivity and Specificity for the Detection of African Swine Fever Virus-Specific IgM and IgG Antibodies.
Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and Evaluation of Three Indirect ELISA Methods Based on Novel Recombinant ASFV Antigens for Serological Detection of African Swine Fever.Pathogens (Basel, Switzerland) · 2026Article
- A Novel In-Cell ELISA With Superior Sensitivity and Specificity for the Detection of African Swine Fever Virus-Specific IgM and IgG Antibodies.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever (ASF), a high-profile transboundary animal disease caused by ASF virus (ASFV), imposes a devastating impact on the global swine industry. Given that vaccines are still under development, including field evaluations, early detection of ASFV is crucial for effective disease control and mitigation. Although PCR is the primary viral detection method of acute or subacute ASFV infections, antibody detection plays a unique role in detecting low-virulent ASFV infection, identifying recovered animals, and tracking viral transmission. ELISA for ASFV antibody detection is commonly used for initial serological screening. To avoid false positive results, the World Organisation for Animal Health (WOAH) recommends using a second serologic method, such as the indirect immunofluorescence assay (IFA), indirect immunoperoxidase test (IPT), or immunoblot test, to confirm the ELISA-positive cases. This strategy improves specificity but not sensitivity (i.e., false negative cases persist). To address this issue, a novel in-cell ELISA (icELISA) was developed in this study. Receiver operating curve analysis of the icELISA revealed the optimized cutoff value of sample-to-positive ratio (S/P ratio) was at 47% with 99.46% analytical sensitivity and 99.43% analytical specificity. Results of the comparative diagnostic sensitivity analysis showed that positive detections of icELISA (150 samples) surpassed a blocking ELISA-IPT combination (132 samples) by 18 samples. Further investigation revealed that the 18 samples contained ASFV-specific immunoglobulin M (IgM) antibodies instead of immunoglobulin G (IgG). The results suggested the icELISA can detect both ASFV-specific IgG and IgM, which outperforms a blocking ELISA-IPT combination in earlier detection, particularly when only IgM antibody is present in a test sample.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.